News

Boehringer partners Tempus AI to enhance cancer therapy pipeline
Boehringer will gain access to the de-identified database of Tempus, which comprises clinical, imaging and molecular data.
Biovica Collaborates with Tempus to Expand the Commercial Reach of DiviTum(R) TKa
UPPSALA, SE / ACCESS Newswire / May 13, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a ...
AOL13d
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this.
Business Wire16d
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication ...
Benzinga.com21d
Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move?
Tempus AI announces a multi-year collaboration with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology. Tempus says the collaboration includes $200 million in data ...